Please login to the form below

Not currently logged in
Email:
Password:

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace
AstraZeneca, Marc Dunoyer

AstraZeneca (AZ) has announced that Marc Dunoyer will take over from Simon Lowth as the company's chief financial officer.

The decision ends a near four-month search for a replacement after Lowth announced in July his intention to leave the company for a similar role at natural gas firm BG Group.

Dunoyer only joined AZ in June this year as executive VP, global portfolio and product strategy, to support the company's global restructuring programme. He was previously head of the rare diseases business at big pharma rivals GlaxoSmithKline (GSK).

AZ's CEO Pascal Soriot said he was “delighted” with the appointment of Dunoyer.

“Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership,” said Soriot.

Dunoyer will begin his new role on November 1, reporting directly to Soriot.

AZ said his replacement as as executive VP, global portfolio and product strategy will be announced separately.

1st November 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics